Avid Bioservices, Inc. reiterating revenue guidance for the fiscal year 2022. The company is reiterating revenue guidance for fiscal 2022 of $115 million to $117 million, a 20% to 22% increase over fiscal 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.63 USD | -4.26% | -11.48% | +17.39% |
30/04 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
29/04 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.39% | 484M | |
-0.28% | 90.59B | |
-0.92% | 38.99B | |
-9.57% | 34.09B | |
-17.98% | 15.02B | |
-6.74% | 13.17B | |
-9.76% | 11.88B | |
-47.31% | 10.65B | |
+7.42% | 9.25B | |
+137.06% | 9.02B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022